Clinical Trial Update: Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the optimal timing of the PET tracer rhPSMA-7.3 (18F) to identify sites of recurrent prostate cancer after radical pros…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• rhPSMA 7.3 (18F)

Snippet

Sponsor: NYU Langone Health | Conditions: Prostate Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2026-03-25